Upstate Active Clinical Trials

Study Title:

AMG 592 - A Phase 2b Dose Ranging Study to Evaluate the Efficacy and Safety of Efavaleukin Alfa in Subjects with Active Systemic Lupus Erythematosus with Inadequate Response to Standard of Care Therapy 20200234

Upstate Institutional Review Board (IRB) Number:

1746887

Study/Protocol ID:

20200234

Patient Age Group:

Adults

Principal Investigator:

Andras Perl, MD, PhD

Who can I contact for more information?

Name: Joanne M Chilton, CCRP
Phone: 315-464-8240
Email: chiltonj@upstate.edu

Return to Previous Page || Search Again